Scholarlink

<p>As the number of systemic agents available for the treatment of moderate-to-severe atopic dermatitis (AD) continues to increase, it is likely that patients may need or want to switch from one treatment to another. Owing to differences in the mechanism of action, the systemic agents abrocitinib (an oral Janus kinase 1-selective inhibitor) and dupilumab (an injectable interleukin 4 alpha antagonist) are associated with distinct efficacy and safety profiles. Two recent publications have examined the efficacy and safety of long-term abrocitinib in patients previously treated with dupilumab. In this podcast article, two dermatologists discuss the management of moderate-to-severe AD and highlight factors to consider before changing therapies in the context of these recent studies, focusing on switching from dupilumab to abrocitinib treatment.</p><p>Below is the link to the electronic supplementary material.<MediaObject ID="MOESM1"> <VideoObject FileRef="MediaObjects/13555_2025_1491_MOESM1_ESM.mp4" VideoID="5fcb7BuwFDVRn-95xqqwJ4"> <Caption Language="En" xml:lang="en"> <CaptionContent> <p>Supplementary file1 (MP4 173881 KB)</p> </CaptionContent> </Caption> </VideoObject> </MediaObject></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Switching from Dupilumab to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Podcast Article

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月6日

查看全文
  • Vivian Y. Shi,
  • Erman Güler,
  • Brian Esparza,
  • Jonathan I. Silverberg

摘要

As the number of systemic agents available for the treatment of moderate-to-severe atopic dermatitis (AD) continues to increase, it is likely that patients may need or want to switch from one treatment to another. Owing to differences in the mechanism of action, the systemic agents abrocitinib (an oral Janus kinase 1-selective inhibitor) and dupilumab (an injectable interleukin 4 alpha antagonist) are associated with distinct efficacy and safety profiles. Two recent publications have examined the efficacy and safety of long-term abrocitinib in patients previously treated with dupilumab. In this podcast article, two dermatologists discuss the management of moderate-to-severe AD and highlight factors to consider before changing therapies in the context of these recent studies, focusing on switching from dupilumab to abrocitinib treatment.

Below is the link to the electronic supplementary material.

Supplementary file1 (MP4 173881 KB)